Implementing Precision Medicine in cOmmunity HospiTALs

Launched by GUSTAVE ROUSSY, CANCER CAMPUS, GRAND PARIS · Mar 7, 2022

Keywords

ClinConnect Summary

This clinical trial, titled "Implementing Precision Medicine in Community Hospitals," is focused on improving treatment for patients with metastatic cancer, which is cancer that has spread from its original site to other parts of the body. The study will explore how a special test called a liquid biopsy can help doctors understand the cancer better and tailor treatments specifically to each patient’s needs. The trial is currently recruiting participants who are 18 years or older and have certain types of advanced solid tumors that are not easily treatable by surgery.

To be eligible to join the study, participants must have measurable cancer that meets specific criteria and a good performance status, which means they can carry out daily activities without significant limitations. However, individuals with certain other medical conditions, recent cancer diagnoses, or those who are pregnant or breastfeeding cannot participate. If eligible, participants can expect to provide a blood sample for the liquid biopsy and may receive personalized treatment recommendations based on the results. This trial offers a chance to contribute to important research that may lead to better cancer care in community settings.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Participants are eligible to be included in the study only if they meet all of the following criteria:
• • 1. Age ≥ 18 years
• • 2. Histology: solid malignant tumor
• • 3. Locally advanced/unresectable and/or metastatic (for prostate cancer: castration resistant prostate cancer, for RH+/HER2- breast cancer: prior treatment with endocrine therapy plus anti-CDK4/6 inhibitor)
• • 4. Eastern Cooperative Oncology Group (ECOG) performance status \< 2
• • 5. Measurable disease as per RECIST criteria
• • 6. Patient with a social security in compliance with the French law relating to biomedical research (Article L.1121-11 of French Public Health Code)
• • 7. Voluntary signed and dated written informed consent prior to any study specific procedure.
• Exclusion Criteria:
• Participants will be excluded from the study if they meet any of the following criteria:
• • 1. Radiological evidence of symptomatic or progressive brain metastases
• • 2. Previous or current malignancies of others histologies within the last 2 years, with the exception of in situ carcinoma of the cervix, and adequately treated basal cell or squamous cell carcinoma of the skin and prostate cancer
• • 3. Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in a clinical trial or which would jeopardize compliance with the protocol
• • 4. Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent
• • 5. Minors (Age \< 18 years)
• • 6. Pregnant or breast-feeding women
• • 7. Previous enrollment in the present study.